|
Mode of Action (MoA)
|
binding affinity to SpCas9 was demonstrated using biolayer interferometry, but detailed MoA is unknown.
|
|
Evidence
|
A synthetic E. coli strain was engineered with a genetic circuit where SpCas9 targeted a plasmid-borne chloramphenicol resistance gene. If an anti-CRISPR protein inhibits Cas9, the strain retains chloramphenicol resistance and survives antibiotic selection (ECO_0007003). In vitro cleavage assay evidence (a biochemical assay where purified Cas9 protein and guide RNA are incubated with target DNA and a candidate ACR protein outside of any living cell) further supported anti-CRISPR activity. Direct binding is supported by biolayer Interferometry evidence (ECO_0006350).
|
|
MoA Category
|
binds and inhibits host defence system (putative)
|
|
Subtype(s) of the defence system(s) inhibited by the protein
Defence Subtype
|
Streptococcus pyogenes type II-A CRISPR-Cas
|
|
Relevant publication(s)
DOI
|
10.1016/j.chom.2019.01.003
|
|
Other components of the anti-defence system
Multicomponent System
|
-
|
|
Known structure in PDB
PDB ID
|
-
|
|
Genome(s) encoding the protein
Protein Source
|
Metagenome
|
|
Defence system(s) inhibited by the protein
Defences
|
CRISPR-Cas
|